Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
other
Where this comes from
- Record sourced from PubMed, PMID 25998055.
- Also identified by DOI 10.7554/eLife.06959 and PMC identifier 4441371.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of 50 papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from 'Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs' by Sugahara and colleagues, published in <i>Science</i> in 2010 (Sugahara et al., 2010). The key experiments being replicated include Figure 2 and Supplemental Figure 9A. In Figure 2, Sugahara and colleagues presented data on the tumor penetrance of doxorubicin (DOX) when co-administered with the peptide iRGD, as well as the effect of co-treatment of DOX and iRGD on tumor weight and cell death. In Supplemental Figure 9A, they tracked body weight of mice treated with DOX and iRGD to provide evidence that iRGD does not increase known DOX toxicity. The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange, and the results of the replications will be published by <i>eLife</i>.
Medical subject headings
- Antibiotics, Antineoplastic
- Cell-Penetrating Peptides
- Doxorubicin
- Drug Carriers
- Oligopeptides
- Prostatic Neoplasms